Bank of America’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-360,036
| Closed | -$18.6M | – | 8756 |
|
|
2022
Q3 | $18.6M | Buy |
360,036
+154,318
| +75% | +$6.38M | ﹤0.01% | 2031 |
|
|
2022
Q2 | $5.1M | Sell |
205,718
-95,804
| -32% | -$2.11M | ﹤0.01% | 3373 |
|
|
2022
Q1 | $7.56M | Buy |
301,522
+224,627
| +292% | +$6.31M | ﹤0.01% | 3159 |
|
|
2021
Q4 | $2.8M | Buy |
76,895
+5,810
| +8% | +$204K | ﹤0.01% | 4228 |
|
|
2021
Q3 | $1.22M | Buy |
71,085
+44,591
| +168% | +$695K | ﹤0.01% | 4891 |
|
|
2021
Q2 | $354K | Sell |
26,494
-109,223
| -80% | -$2.69M | ﹤0.01% | 5682 |
|
|
2021
Q1 | $6.95M | Buy |
135,717
+29,793
| +28% | +$1.79M | ﹤0.01% | 3059 |
|
|
2020
Q4 | $6.56M | Sell |
105,924
-14,472
| -12% | -$829K | ﹤0.01% | 2887 |
|
|
2020
Q3 | $6.6M | Buy |
120,396
+66,251
| +122% | +$3.57M | ﹤0.01% | 2650 |
|
|
2020
Q2 | $3.12M | Buy |
54,145
+4,292
| +9% | +$234K | ﹤0.01% | 3276 |
|
|
2020
Q1 | $2M | Buy |
49,853
+11,858
| +31% | +$504K | ﹤0.01% | 3482 |
|
|
2019
Q4 | $1.5M | Sell |
37,995
-40,615
| -52% | -$713K | ﹤0.01% | 4220 |
|
|
2019
Q3 | $533K | Sell |
78,610
-20,694
| -21% | -$155K | ﹤0.01% | 5042 |
|
|
2019
Q2 | $923K | Buy |
99,304
+6,487
| +7% | +$75.1K | ﹤0.01% | 4620 |
|
|
2019
Q1 | $1.29M | Sell |
92,817
-806
| -0.9% | -$9.22K | ﹤0.01% | 4323 |
|
|
2018
Q4 | $1.02M | Sell |
93,623
-8,177
| -8% | -$86.2K | ﹤0.01% | 4389 |
|
|
2018
Q3 | $1.29M | Sell |
101,800
-71
| -0.1% | -$855 | ﹤0.01% | 4315 |
|
|
2018
Q2 | $1.34M | Buy |
101,871
+16,734
| +20% | +$200K | ﹤0.01% | 4279 |
|
|
2018
Q1 | $1.16M | Sell |
85,137
-6,094
| -7% | -$62.9K | ﹤0.01% | 4294 |
|
|
2017
Q4 | $543K | Buy |
91,231
+34,140
| +60% | +$234K | ﹤0.01% | 4894 |
|
|
2017
Q3 | $424K | Buy |
57,091
+11,223
| +24% | +$93.3K | ﹤0.01% | 5050 |
|
|
2017
Q2 | $429K | Sell |
45,868
-67,253
| -59% | -$494K | ﹤0.01% | 4972 |
|
|
2017
Q1 | $824K | Sell |
113,121
-45,266
| -29% | -$326K | ﹤0.01% | 4552 |
|
|
2016
Q4 | $1.17M | Sell |
158,387
-162,820
| -51% | -$1.17M | ﹤0.01% | 4211 |
|
|
2016
Q3 | $1.94M | Sell |
321,207
-119,888
| -27% | -$567K | ﹤0.01% | 3661 |
|
|
2016
Q2 | $1.98M | Buy |
441,095
+342,106
| +346% | +$1.28M | ﹤0.01% | 3629 |
|
|
2016
Q1 | $246K | Buy |
98,989
+59,137
| +148% | +$215K | ﹤0.01% | 5033 |
|
|
2015
Q4 | $323K | Buy |
39,852
+30,452
| +324% | +$216K | ﹤0.01% | 5079 |
|
|
2015
Q3 | $57K | Buy |
9,400
+88
| +0.9% | +$636 | ﹤0.01% | 5908 |
|
|
2015
Q2 | $76K | Sell |
9,312
-50
| -0.5% | -$397 | ﹤0.01% | 5747 |
|
|
2015
Q1 | $71K | Buy |
9,362
+62
| +0.7% | +$484 | ﹤0.01% | 5494 |
|
|
2014
Q4 | $63K | Hold |
9,300
| – | – | ﹤0.01% | 6192 |
|
|
2014
Q3 | $42K | Sell |
9,300
-27,146
| -74% | -$143K | ﹤0.01% | 6626 |
|
|
2014
Q2 | $213K | Sell |
36,446
-2,309
| -6% | -$13K | ﹤0.01% | 5501 |
|
|
2014
Q1 | $257K | Sell |
38,755
-9,987
| -20% | -$69.4K | ﹤0.01% | 5218 |
|
|
2013
Q4 | $282K | Sell |
48,742
-4,934
| -9% | -$25.4K | ﹤0.01% | 5276 |
|
|
2013
Q3 | $299K | Sell |
53,676
-16,111
| -23% | -$174K | ﹤0.01% | 5086 |
|
|
2013
Q2 | $986K | Buy |
+69,787
| New | +$904K | ﹤0.01% | 4057 |
|
Other funds holding CCXI
Bank of America's CCXI Position: Q4 2022 in Review
Bank of America sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 360,036 shares — an estimated $18.6M sold.
Bank of America first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $18.6M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Bank of America reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Bank of America sold 360,036 ChemoCentryx, Inc. shares in Q4 2022, an estimated $18.6M.
- Bank of America first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- Bank of America's ChemoCentryx, Inc. position peaked at $18.6M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Bank of America's 13F filing for Q4 2022, filed 10 Feb 2023.